CN104415739A - Application of styrene-divinylbenzene medical resin - Google Patents
Application of styrene-divinylbenzene medical resin Download PDFInfo
- Publication number
- CN104415739A CN104415739A CN201310379949.2A CN201310379949A CN104415739A CN 104415739 A CN104415739 A CN 104415739A CN 201310379949 A CN201310379949 A CN 201310379949A CN 104415739 A CN104415739 A CN 104415739A
- Authority
- CN
- China
- Prior art keywords
- resin
- amino acid
- divinylbenzene
- styrene
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011347 resin Substances 0.000 title claims abstract description 31
- 229920005989 resin Polymers 0.000 title claims abstract description 31
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 239000011148 porous material Substances 0.000 claims abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000003463 adsorbent Substances 0.000 claims abstract description 4
- 239000000523 sample Substances 0.000 claims abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 108091035707 Consensus sequence Proteins 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 108091036078 conserved sequence Proteins 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 26
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 208000030507 AIDS Diseases 0.000 description 11
- 239000000370 acceptor Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 4
- 108010041397 CD4 Antigens Proteins 0.000 description 4
- 241000446313 Lamella Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 208000031957 HIV carrier Diseases 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004970 cd4 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 2
- 229940005991 chloric acid Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- HLTUZPFCDXKNKS-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene ethene Chemical compound C(=C)C1=C(C=CC=C1)C=C.C=C HLTUZPFCDXKNKS-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000007438 host cellular process Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/48—Sorbents characterised by the starting material used for their preparation
- B01J2220/4812—Sorbents characterised by the starting material used for their preparation the starting material being of organic character
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an application of styrene-divinylbenzene medical resin. Micro pores with a pore size of 70-140 nanometers are densely distributed on a resin ball of the styrene-divinylbenzene medical resin, wherein a specific surface area of the resin ball is greater than 1000 square meters/gram, and the pore volume of the micro pores of the resin ball is greater than 6.000e-01cc/gram. The application of the styrene-divinylbenzene medical resin is characterized in that the resin is constructed as electron cloud field force, gp120 and gp41 amino acid conserved sequence target site adsorbents, wherein the electron cloud field force is formed by taking the pore size and the additional charge inside the resin as the principle thing; a protein film coats on the surface of the resin, and the specific amino acid short peptides of the loaded gp120 and gp41 amino acid conserved sequences are used as target probes.
Description
Technical field
The invention belongs to medical macromolecular materials, specifically a kind of electron cloud field force intervenes the target absorption large aperture resin particle of HIV acceptor groups two dimension dynamic structure and the preparation and application of adsorption column.
Background technology
Human immunodeficiency syndrome be cause after a kind of HIV infection with immune system damage for main disease, AIDS is the disease of involving whole body multiple organ system, mucocutaneous, lymph node, eye, respiratory system, digestive system, nervous system, urinary system etc.Except immune system pathology, also comprise multisystem opportunistic infections (as virus, bacterium, fungi and protozoon) and malignant tumour (comprising Kaposi's sarcoma, malignant lymphoma and cervix cancer), constitute the clinical pathology change of AIDS complexity.The WHO report whole world in 2010 survival HIV carriers and AIDS patient totally 3,400 ten thousand, new infeetioa 2,700,000, annual dead 1,800,000 people.Have every day more than 7000 people's new infections, district from all parts of the world all has popular, but more than 97% in, low income country, especially attach most importance to Africa.China CDC estimates, ends to the end of the year 2011, China survival HIV carriers and AIDS patient about 780,000 people, annual new infections person 4.8 ten thousand people, dead 2.8 ten thousand people.Epidemic situation has covered national all provinces, autonomous regions and municipalities, and current China faces AIDS morbidity and dead peak period, and spreads to population by the people at highest risk such as drug abuse, unlicensed prostitute.
HIV belongs to the mankind slow virus group in Retroviridae lentivirus, be divided into 1 type and 2 types, Major Epidemic HIV-1 in current world wide, HIV-1 is 20 body cubic symmetry, diameter about 100 ~ 120nm spheric granules, be made up of core and coating two parts, core comprises two single-stranded RNA chains, core texture albumen and the necessary enzyme of virus replication, containing reverse transcriptase, integrase and protease.HIV-1 is optionally adsorbed on the CD4 acceptor of target cell, under the help of accessory receptor, enters host cell after infecting human body.Through cyclisation and integration, transcribe and translate, assemble, ripe and sprout, form ripe virion.HIV need enter cell by means of the acceptor on permissive cell surface, comprises the first acceptor and Co receptor.After HIV enters human body, in 24-48 hour, arrive regional nodes, within about about 5 days, viral composition can be detected in peripheral blood.Then produce viremia virusemia, cause acute infection.Because human immune system is mainly through for each strain specific antibodies of HIV albumen, the reaction of specific C D4+T lymphocyte immunity and CTL directly or secrete various cell factor (as TNF, interferon etc.), suppress virus replication, but the immune system of body can not remove virus completely, final formation chronic infection, enters incubation period.HIV virus is constantly bred in human body, patient CD4+T LC obviously declines, and many < 200/mm3, HIV plasma viral load obviously raises, showing as HIV related symptoms, various opportunistic infections and tumour, is the terminal stage after infected by HIV.
HIV causes patient to occur body dysfunction, is in progress as AIDS principal immune pathologic basis is that CD4+T lymphocyte quantity reduces.After infected by HIV, in body, CD4+T lymphocyte quantity constantly reduces, be divided into 3 stages: 1. acute infection period: CD4+T lymphocyte quantity is transient rapid minimizing in a short time, most of the infected is without special treatment, and CD4+T lymphocyte number can return to normal level or voluntarily close to normal level; 2. the symptomless infection phase: CD4+T lymphocyte quantity continues slowly to reduce, how between 800 ~ 350/mm3, this periods of months to ten several years phase not etc., does not on average continue about about 8 years; 3. the symptom phase is had: the minimizing faster again of CD4+T lymphocyte, how at below 350/mm3, part end-stage patients are down to below 200/mm3, and reduce fast.T helper cell 1 (Th1) cell is replaced by t helper cell 2 (Th2) cell, antigen presenting cell function is impaired, interleukin 2 produces and reduces and lose antigen reaction activity power, makes the various infection of patient HIV/AIDS Yi Fasheng.
Anti-hiv therapy therapeutic purpose: suppress copying of virus to greatest extent, Save and restore immunologic function, reduces case fatality rate and the diseases related incidence of disease of HIV, improves the quality of life of patient, reduce the propagation of AIDS.HAART (Highly Active Antiretroviral Therapy, HAART) is the most basic methods for the treatment of of AIDS, needs to take medicine throughout one's life.Current anti-retroviral (ARV) medicine has six large classes kind more than 30.Ucleosides reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (Pls), integrase inhibitor (raltegravir), fusion enzyme inhibitor (FIs) and CCR5 suppress neat (maraviroc).
Both at home and abroad about the research of aids prevention and treatment is carried out continual, regrettably all the failing for the treatment of of current all about prevention, within 2007, Merck & Co., Inc. announces vaccine development failure, within 2009, NIH declares vaccine research failure, being the failure of vaccine research on the one hand, is the exposure of a large amount of people at highest risk on the other hand.Simultaneously along with the carrying out of antiviral therapy, a large amount of antibody-resistant bacterium occurs, especially the toxic and side effect of antiviral therapy medicine, economic factor, patient compliance decline and treatment lack of standardization, antiviral failed, immuning failure is caused to occur in a large number to clinical failure, the failed initiation functional of serial therapy, there is clinical complication in patient, quality of life declines and disables, and causes a large amount of burden on societys.
For the failure of antiviral therapy, have and consider new methods for the treatment of, wherein blood purification treatment is constantly attempted, but HIV virus presents highly divergent isolate in human body environment, structure is changeable, simple adsorbing therapy is difficult to effectively remove virus, especially the removing being combined virus with CD4 is difficult to realize, be difficult to reach result for the treatment of, the application number that Wuhan University 2012.4.23 applies for is the patent of 201210118840.9, be improved the design of compatibility adsorbing therapy HIV, but, due to gp120 variability, functional group is changeable, affinity antibody is difficult to reach affine effect, especially albumen affinity antibody, passing through sterilization, in pathogenic microorganism inactivation process, albumen affinity receptor is very easy to deactivation, a small amount of remaining acceptor, because between each subunit of gp120 acceptor, molecule dynamic cooperating measure needs power, subunit group is needed to expose with the affine combination of conserved positions, also be single affine unapproachable.
Summary of the invention
The object of the invention is that the difficult point overcoming existing treating AIDS is with not enough, according to electron cloud field force, gp120 acceptor, the protein science feature of gp41 acceptor groups, for gp120, gp41 subunit amino acid conserved sequence is target spot, design height specific amino acid probe, specific binding HIV virus, according to gp120, gp41 subunit is in conjunction with the dynamic translation feature of two-dimensional structure after CD4 acceptor, the mechanics scope of two-dimensional space cooperating measure when going out gp120 specific binding CD4 according to steered molecular dynamics model inspection, the electron cloud field force that the target designing a kind of particular range combines intervenes the ethene-divinylbenzene material macroporous resin microspheres of HIV functional group dynamic structure conversion, microballoon itself is with hollow hole, specific designs pore size, siphon power is produced after meeting AIDS patient's environment, this siphon power can effectively adsorb HIV virion in human internal environment, particle surface wraps up protein envelope and does not destroy human normal structure, with this microballoon for adsorption column prepared by host material, oral granule removes AIDS virus, reach the object for the treatment of.
The medical macroporous absorbent resin of the present invention be using styrene-divinyl benzene resin ball as electron cloud field force, the medical polymeric adsorbent of gp120, gp41 amino acid consensus sequence target site adsorbent framework, its resin balls is gathered micropore, and pore diameter range is in 70-140 nanometer; Resin balls specific area be greater than 1000 square meters/gram; Resin balls Micropore volume is greater than 6.000e-01cc/ gram; Resin inside is the theme with aperture and additional charge, forms electron cloud field force, Surface coating protein film, is loaded into gp120, gp41 amino acid consensus sequence specific amino acid small peptide as target spot probe.Coated with resin can process as required with polarity, shows as negativity, keeps containing more positively charged chloro acid residue with V3 district, reduces the variation of viral high saltation zone, solves the removing of antiviral therapy resistance HIV Strain.
Research finds: pl20 molecular structure feature and functional localization gpl20 molecule hold C to hold can be divided into successively T cell tropism major decision bunch, monocyte tropism major decision bunch, V3 ring, CD4 land, gpl20 and gp41 cutting area, corresponding circle of sensation and cross-film district from the N of protein peptide chain, gpl20 there are 2 domains with strong conserved sequence, play the effect of the binding site of the acceptors such as covering and hiding host cell surface CD4/CCR5/CXCR4; Simultaneously, the c-terminus of gpl20 also has 3 to have certain conservative but discontinuous sequence forms the binding domain of CD4 molecule jointly, between them, section has the amino acid sequence separation of the high frequency of mutation, thus makes immune response be difficult to play effective immune clearance effect for the binding site on gpl20; In addition, gpl20 surface also exists 5 region of variability (variable region, V district), wherein V3 district is the most important, research finds that the Neutralization and crystallization of HIV 1 is present on V3 ring, V3 ring is the critical function district of envelope protein, also be that HIV-I enters the most important link of host cell process simultaneously, V3 ring is atypical circulus, be made up of about 35 ~ 36 amino acid residues, respectively there are one and half Guang chloric acid at two ends, and form disulfide bond each other and connect, its secondary structure is irregular.Research shows that V3 district is containing more positively charged chloro acid residue, and its corresponding co-receptor CXCR4 and CCR5 contains more electronegative amino acid residue, in V3 district, the arginine of N mono-end can affect the interaction with CCR5 with the replacement of the hydrophobic amino acid phenylalanine near top, V3 district.Research also shows that V3 district has 6 amino acid residues to play an important role in the interaction process of gpl20 and cCR5, comprise arginine 303 ~ 11 third chloric acid 333 residue of the base portion being positioned at V3 ring, with the lysine 310 of D lamella being positioned at V3 ring both sides, isoleucine 312, arginine 318 and phenylalanine-3,4-quinone 20t ~.For this relative conserved sequence, only will merge with the polypeptide of gp120 specific binding and Fc fragment or ETA, and then formed only for the specific fusion protein polypeptide of gp120, formed in conjunction with target position, covalent bond.Form resin microsphere specific adsorption site, be that lasting electron cloud field force intervenes gp120 two-dimensional structure, destroy and CD4 receptors bind, reduce lymphocyte under fire with damage, keep HIV virus free state, reach the effect that resin high-efficient cleaning removes.
Gp120-CD4 is combined with Chemokines CC XCR4 or CXCR5 of target cells and forms CD4-gp120-CXCR4/CXCR5 tri-molecular complex, after compound is formed, gp41 exposes, play a part bridge wherein, utilize self hydrophobic effect mediate retroviral cyst membrane and cell membrane fusion, finally cause cell to be destroyed.Prepare the monoclonal antibody (mAb) of anti-HIV-1 gp41 improvement on synthesis gp41-5, the 4 strain mAb obtained can the new target instrument of the space conformation domain of specific bond gp41 core textures, form secondary target to combination, remove the HIV structure that gp120 can not intervene completely, formed and remove HIV dual structure, this is also a bright spot of the present invention, namely can remove the HIV be combined with cd4 cell.
Based on gpl20 functional structure and steered molecular dynamics, detect the required power size that gp120 changes in conjunction with cd4 cell time space two-dimensional structure, abundant utility tree lipid microspheres spinning electron cloud field force, intervene and change gpl20 two-dimensional structure, destroy gpl20 and CD4 receptor binding capacity, this is also specificity of the present invention and uniqueness characteristic.
Gpl20 core texture by X-ray crystal diffraction technology to itself and acceptor CD451] parsing of the crystal complex structure of antibody 17b draws, the core of gpl20 comprises inner domain and outer domains 2 main domains and so-called " bridge lamella " structure, in this crystal complex, gPl20 core texture does not comprise N mono-and C mono-end, V1/V2 and V3 and V4 ring structure, however, this composite structure shows, from gpl20 inner domain, some structural constituent of outer domains and bridge lamella all interacts with CD4 molecule, these interact gpl20 molecule stable at CD4 combination (CD4 mono-bound) conformational state. simultaneously, this composite structure is that analysis gpl20 antigen site and HIV mechanism provide architecture basics.
Steered molecular dynamics is based on the main movement pattern of gp120, main manifestations is inner domain, outer domains, rotation/distortion between bridge lamella and V3 ring, flexing/closedown, the combination of prolongation/compression movement or these motion modes, utilize the mutual transfer capability between the different conformation of essential sub-space overlap algorithm evaluation gp120, result shows, before CD4 combines, state (unliganded) gp120 is better than ability to removing CD4 composite form (CD4-free) and transforming to the ability that composite form (CD4-complexed) transforms, and CD4-freegp120 has the stronger ability to condition conversion before combining than CD4-complexed gp120. with the relation of gp120 dynamic structure and function, calculate the field force size that gp120 Different Dynamic cooperating measure needs, decision tree lipid microspheres electron cloud field force scope, restriction gp120 dynamic structure transfer capability, reach and intervene gp120 two-dimensional space conversion effect, control gp120 and CD4 combines.
Claims (2)
1. the application of styrene-divinylbenzene medical resin, its resin balls is gathered micropore, and pore diameter range is in 70-140 nanometer; Resin balls specific area be greater than 1000 square meters/gram; Resin balls Micropore volume is greater than 6.000e-01cc/ gram; It is characterized in that:
Using this resin as electron cloud field force, gp120, gp41 amino acid consensus sequence target site adsorbent framework, resin is inner based on aperture and additional charge, forms electron cloud field force; The coated protein film of resin surface, is loaded into gp120, gp41 amino acid consensus sequence specific amino acid small peptide as target spot probe.
2. styrene-divinylbenzene medical resin as claimed in claim 1, is characterized in that:
Described coated with resin can process as required with polarity, shows as negativity, keeps containing more positively charged chloro acid residue with V3 district, reduces the variation of viral high saltation zone, solves the removing of antiviral therapy resistance HIV Strain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310379949.2A CN104415739A (en) | 2013-08-28 | 2013-08-28 | Application of styrene-divinylbenzene medical resin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310379949.2A CN104415739A (en) | 2013-08-28 | 2013-08-28 | Application of styrene-divinylbenzene medical resin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104415739A true CN104415739A (en) | 2015-03-18 |
Family
ID=52966518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310379949.2A Pending CN104415739A (en) | 2013-08-28 | 2013-08-28 | Application of styrene-divinylbenzene medical resin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104415739A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1130911A (en) * | 1993-09-13 | 1996-09-11 | 阿尔梅尔股份有限公司 | Multi-branched peptide constructs for combating HIV |
| CN101899164A (en) * | 2009-05-25 | 2010-12-01 | 于杰 | Improvement of phenylethylene-divinylbenzene adsorbent resin post-crosslinking process |
| CN102066418A (en) * | 2007-11-19 | 2011-05-18 | 国立大学法人熊本大学 | Anti-HIV monoclonal antibody |
| CN102294229A (en) * | 2010-06-24 | 2011-12-28 | 于杰 | Synthesis formula of ultrahigh cross-linked styrene macroporous adsorbent and process route thereof |
| CN102361658A (en) * | 2009-01-22 | 2012-02-22 | 弗雷森纽斯医疗护理德国有限责任公司 | Sorbent for removing protein-bound substances |
| CN102847521A (en) * | 2011-06-28 | 2013-01-02 | 于杰 | Macro-porous adsorption resin and its application |
-
2013
- 2013-08-28 CN CN201310379949.2A patent/CN104415739A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1130911A (en) * | 1993-09-13 | 1996-09-11 | 阿尔梅尔股份有限公司 | Multi-branched peptide constructs for combating HIV |
| CN102066418A (en) * | 2007-11-19 | 2011-05-18 | 国立大学法人熊本大学 | Anti-HIV monoclonal antibody |
| CN102361658A (en) * | 2009-01-22 | 2012-02-22 | 弗雷森纽斯医疗护理德国有限责任公司 | Sorbent for removing protein-bound substances |
| CN101899164A (en) * | 2009-05-25 | 2010-12-01 | 于杰 | Improvement of phenylethylene-divinylbenzene adsorbent resin post-crosslinking process |
| CN102294229A (en) * | 2010-06-24 | 2011-12-28 | 于杰 | Synthesis formula of ultrahigh cross-linked styrene macroporous adsorbent and process route thereof |
| CN102847521A (en) * | 2011-06-28 | 2013-01-02 | 于杰 | Macro-porous adsorption resin and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Flazinamide, a novel β-carboline compound with anti-HIV actions | |
| Connell et al. | Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition | |
| Welch et al. | Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance | |
| Wang et al. | Sifuvirtide, a potent HIV fusion inhibitor peptide | |
| Scutari et al. | The role of HIV infection in neurologic injury | |
| Naider et al. | Peptides in the treatment of AIDS | |
| Angamuthu et al. | Antiviral study on Punica granatum L., Momordica charantia L., Andrographis paniculata Nees, and Melia azedarach L., to human herpes virus-3 | |
| Bon et al. | Peptide-derivatized SB105-A10 dendrimer inhibits the infectivity of R5 and X4 HIV-1 strains in primary PBMCs and cervicovaginal histocultures | |
| Siniavin et al. | Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2 | |
| CN108727475B (en) | Lipopeptide potently inhibiting HIV, its derivatives, its pharmaceutical compositions and uses thereof | |
| Ferir et al. | Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120 | |
| CN104415739A (en) | Application of styrene-divinylbenzene medical resin | |
| CN110066317B (en) | Dimer polypeptide with antibacterial and immunoregulation double functions and application thereof | |
| Zhang et al. | Structural insights into the mechanisms of action of short-peptide HIV-1 fusion inhibitors targeting the Gp41 pocket | |
| Fernández-Ortega et al. | Non-induced leukocyte extract reduces HIV replication and TNF secretion | |
| Ren-Rong et al. | Anti-HIV-1 activities of hemslecins A and B | |
| Li et al. | Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission | |
| Jagtap et al. | Modelling and docking of Indian SARS-CoV-2 spike protein 1 with ACE2: implications for co-morbidity and therapeutic intervention | |
| CN102755335A (en) | Application of triptolide in preparation of medicament for treating or preventing human immunodeficiency viruses (HIV) | |
| Neogi et al. | Genetic architecture of HIV-1 genes circulating in north India & their functional implications | |
| Barrish et al. | Antiviral agents | |
| CN116003258B (en) | 12-O-octanoyl-phorbol ester derivative and preparation method and application thereof | |
| TW201229241A (en) | Method for screening and purifying enterovirus, method for mass-producing enterovirus, and method for manufacturing enterovirus vaccine | |
| CN108676071B (en) | anti-Abeta protein aggregation heptapeptide, application thereof and gene for encoding synthetic polypeptide | |
| CN102205111B (en) | Application of agrocybe aegerita galactose agglutinin in preparation of anti-HIV (Human Immunodeficiency Virus) infection medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150318 |